top of page

DIOSynVax needle-free vaccine for COVID-19 enters clinical trial

Our new vaccine designed to protect against all Sarbeco Coronaviruses with the potential to protect against the variants of SARS-CoV-2 is now in Phase I Clinical Trials

Phase I Vaccine Study

There is currently no licensed vaccine that can protect across a whole range of the family of Coronaviruses that affect humans (known as Sarbeco Coronaviruses), such as SARS-CoV-2 which causes COVID-19, and SARS. Whilst highly effective vaccines have been produced for COVID-19, variants of the virus have evolved which are somewhat able to evade the immune responses given by vaccination or by previous infection.


It is therefore important to develop a vaccine with a very broad range of coverage across the SARS-CoV-2 virus that causes COVID-19, and all its relatives. A vaccine that protects against other Sarbeco coronaviruses will also be useful to provide protection against future potential pandemic viruses. Read more about on the BMC clinical trial registry on how we're currently using different doses to ensure its safety and test its immune responses in healthy volunteers.

Trial Purpose

The prevention of COVID-19 and other severe beta-coronavirus infections

bottom of page